Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.

Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies. 

Wow! 2022 has been an exciting year of new challenges, amazing successes, and incredible opportunities. And we couldn't have gotten through it all without YOU! Before we wrap up the top stories and new features from OncData this year, we want to take time to thank each and every one of YOU: doctors, nurses, medical staff, and all frontline workers for your continued dedication. You continue to inspire us each and every day. THANK YOU!

In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, an Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma. 

In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee,Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma.  

Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.  

In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.  

Research has shown that Black American patients with multiple myeloma experience significant disparities in treatment patterns and outcomes compared with White patients. In this interview, Oncology Data Advisor editorial board member Dr. Rahul Banerjee speaks with Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas Medical School and a leading researcher in the field of multiple myeloma treatment disparities. Dr. Al Hadidi explains the differences in disease biology and treatment outcomes experienced by Black patients and shares solutions for closing this gap and ensuring equal access to care for all patients with multiple myeloma.  

In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Korde of Memorial Sloan Kettering Cancer Center about the potential of digital health tools to improve quality of life for patients with multiple myeloma.  

In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty of Columbia University Irving Medical Center about risk factors for the development of venous thromboembolism (VTE) in patients with multiple myeloma and the considerations for thromboprophylaxis during their treatment.  

Rahul Banerjee, MD, and Kelly Brassil, PhD, RN, FAAN.

Patients undergoing autologous stem cell transplant (ASCT) for multiple myeloma face significant challenges in quality of life, including anxiety, acute symptom burden, and decreased physical function. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Rahul Banerjee and Dr. Kelly Brassil presented their research regarding digital life coaching for this patient population. In this interview with Oncology Data Advisor, Dr. Banerjee and Dr. Brassil discuss their results from a prior pilot study on this topic, the design of an ongoing phase 2 trial to continue the research, and its implications for improving the quality of life for patients undergoing ASCT for multiple myeloma.